Kabra Drugs Ltd.

KABRADG

₹12.21

0% (0)

Market Cap

₹29 Cr.

P/E

0.00

Key Ratios

Edit Ratio's

Market cap

29.00 Cr

Prom Holding

ROE (%)

-67.98

ROCE (%)

-67.93

Div Yield (%)

Sales

OPM (%)

Debt to Equity

-1.16

Edit Ratio's

About

Kabra Drugs Ltd was incorporated in 1989. They manufacture injectables, liquids, soft gel cap,… Read more

Low

52W Range

High

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Balance sheet
Net Block	2.73	2.48	0.11	0.08	0.04	0.01	—	—	—	0.04
Shareholders Funds	2.63	2.55	0.20	0.03	-0.03	-0.21	-0.39	-0.73	1.08	24.66
Profit & Loss
Operating Profit	0.46	0.44	-1.03	-0.14	-0.05	-0.15	-0.18	-0.34	-0.74	—
Net Sales	9.65	7.61	2.01	—	—	—	—	—	—	—
Cash flow
Cash from Operating Activity	0.28	0.31	-0.12	-0.18	-0.05	-0.25	-0.13	-0.35	-0.21	-4.71
Net Capex (est)	0.31	0.00	-1.50	—	-0.01	—	—	—	—	0.05
Ratios
ROCE (%)	4.65	8.64	-558	-329	211	86.66	47.13	46.18	-67.93	—
ROE (%)	1.04	5.10	-1,199	-517	215	86.66	47.16	46.22	-67.98	—

Forensics

6 Yes

Positive for this company

2 Neutral

Neutral for this company

3 No

Negative for this company

6 No Data

Insufficient data to analyse

Accounting & Shareholding

Depreciation Effect

Depreciation accounting is not leading to increase in profits
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Revenue Recognition

Unable to calculate due to limited data
Contingent Liabilities

Unable to calculate due to limited data
Other Income

Unable to calculate due to limited data

Price & Performance

ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Debt

Company might have issues servicing its debt
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Capex vs ROCE

Unable to calculate due to limited data
Current vs Historic Valuation

Unable to calculate due to limited data
Sales Growth

Unable to calculate due to limited data

Revenue mix

Product Wise Break-Up

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Kabra Drugs	12.21	0.00	29	—	—	-67.93	-67.98
Concord Drugs	30.79	91.55	31	54.39	-33.54	6.66	1.4
Vineet Laboratories	28.45	0.00	27	35.85	-62	12.59	2.96
Omkar Pharmachem	25.68	128.84	26	0.03	—	3.09	2.05
Adeshwar Meditex	18.2	12.71	26	57.55	—	13.02	5.75
Zenith Health Care	4.12	330.45	22	28.74	11.53	4.01	2.77
Unick Fix-A-Form	60	12.61	33	71.57	-9.67	11.67	6.2
Panjon	19.5	63.51	33	56.69	165.73	1.6	1.04

FAQs on Kabra Drugs Ltd. Business

What does Kabra Drugs do?

Founded in 1989, Kabra Drugs Ltd is a pharmaceutical company based in Indore, Madhya Pradesh. They specialize in manufacturing injectables, liquids, soft gel caps, solvents, and anaesthetics under Segment A.

Who are the competitors of Kabra Drugs?

Kabra Drugs major competitors are Concord Drugs, Vineet Laboratories, Omkar Pharmachem, Adeshwar Meditex, Zenith Health Care, Unick Fix-A-Form, Panjon.
Market Cap of Kabra Drugs is ₹29 Crs.
While the median market cap of its peers are ₹27 Crs.

Is Kabra Drugs financially stable compared to its competitors?

Kabra Drugs seems to be less financially stable compared to its competitors.
Altman Z score of Kabra Drugs is 0 and is ranked 8 out of its 8 competitors.

View FAQ's On Shareprice

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Kabra Drugs Ltd.

Kabra Drugs Ltd.

Key Ratios

About

Timeline

Company Timeline

6 Yes

2 Neutral

3 No

6 No Data

Accounting & Shareholding

Depreciation Effect

Pledge

Retail Holding

Promoter Holding

Revenue Recognition

Contingent Liabilities

Other Income

Price & Performance

ROE

Share price

Working Capital

Balance Sheet Strength

Debt

Margin Stability

ROCE Strength

Capex vs ROCE

Current vs Historic Valuation

Sales Growth

Product Wise Break-Up

UNLOCK PREMIUM

What does Kabra Drugs do?

Who are the competitors of Kabra Drugs?

Is Kabra Drugs financially stable compared to its competitors?

SIGN UP FOR FREE